GTX-104

DRUG2 trials

Sponsors

Grace Therapeutics Inc.

Conditions

Aneurysmal Subarachnoid HemorrhageAneurysmal Subarachnoid Hemorrhage (aSAH)

Phase 1

Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects

CompletedNCT05418348

Grace Therapeutics Inc.Aneurysmal Subarachnoid Hemorrhage

Start: 2021-08-26End: 2022-02-24Updated: 2023-08-31

Phase 3

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

Active, not recruitingNCT05995405

Grace Therapeutics Inc.Aneurysmal Subarachnoid Hemorrhage (aSAH)

Start: 2023-10-20End: 2024-12-31Target: 100Updated: 2024-10-01

Related Papers

Description of STRIVE-ON Study Protocol: Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Phase III Trial (STRIVE-ON)

Neurocritical Care2025-01-283 citations